Steps taken after granting the Marketing Authorisation 
For procedures finalised after 1 December 2002 please refer to module 8B. 
• 
• 
• 
• 
• 
• 
• 
• 
On 29 March 1999 the Marketing Authorisation Holder submitted an application for a Type II 
variation  relating  to  the  implementation  of  additional  information  in  the  relevant  parts  of  the 
Summary  of  Product  Characteristics  and  Package  leaflet  with  respect  to  an  interaction  with 
ritonavir  and  saquinavir.  The  procedure  started  on  29  March  1999.  The  CPMP  adopted  a 
positive  Opinion  on  22  April  1999.  The  European  Commission  on  9  August  1999  issued  a 
favourable Decision.  
On 5 August 1999 the Marketing Authorisation Holder submitted an application for two Type I 
variations relating to increase the batch size of the active substance of Viagra, sildenafil citrate 
and  to  extend  the  shelf-life  of  Viagra  from  2  to  3  years.  The  procedure  started  on  11  August 
1999.  These  variations  were  approved  by  the  EMEA  on  8  September  1999  and  required 
amendments in the relevant sections of the Commission Decision. The European Commission 
amended the Decision on 14 December 1999. 
On 19 August 1999 the Marketing Authorisation Holder submitted an application for a Type II 
variation  relating  to  the  implementation  of  additional  information  in  the  relevant  parts  of  the 
Summary  of  Product  Characteristics  and  Package  Leaflet  with  respect  to  hypersensitivity 
reactions,  particular  skin  rashes  and  post-marketing  experience  with  respect  to  cardiovascular 
and  cerebrovascular  events.  The  procedure  started  on  27  August  1999.  The  CPMP  adopted  a 
positive Opinion on 21 October 1999. The European Commission on 10 February 2000 issued a 
favourable Decision. 
On 25 January 2000 the Marketing Authorisation Holder submitted an application for a Type I 
variation  to  add  an  alternative  site  for  assembly.  The  procedure  started  on  1  February  2000.  
The variation was approved by the EMEA on 23 February 2000. This variation was approved 
by  the  EMEA  on  23  February  2000  and  did  not  require  any  amendments  to  the  Commission 
Decision.  Changes  were  introduced  in  the  summary  of  the  dossier  and  in  the  manufacturing 
process documentation of the dossier. 
On 5 March 2000, the Marketing Authorisation Holder submitted an application for a Type II 
variation for the implementation of additional information in the relevant parts of the Summary 
of  Product  Characteristics,  Labelling  and  Package  Leaflet  in  response  to  a  request  from  the 
CPMP following review of PSURs and monthly line listings, indicating the need to update the 
SPC  and  Package  Leaflet.  The  variation  concerned  the  use  of  sildenafil  in  combination  with 
alphablockers  and  medicinal  products  with  vasodilating  properties,  the  use  in  patients  with 
concomitant left ventricular outflow obstruction or multiple system atrophy (MSA), a potential 
interaction  with  azithromycin,  and  the  occurrence  of  eye  disorders.  Some  additional  changes 
were  made  in  order  to  comply  with  the  EMEA  templates.  The  procedure  started  on  
17  March  2000.  The  CPMP  adopted  a  positive  Opinion  on  25  May  2000.  The  European 
Commission issued a favourable Decision on 12 September 2000. 
On 21 August 2000, the Marketing Authorisation Holder applied for an alternative supplier for 
a  starting  material  used  in  the  synthesis  of  sildenafil.  This  variation  falls  within  the  scope  of 
item  No  11b  of  Annex  I  of  Commission  Regulation  (EC)  No.  542/95  of  10  March  1995,  as 
amended. The procedure started on 29 August 2000. The EMEA considered this variation to be 
acceptable and issued on 28 September 2000 a positive Notification. 
On  21  August  2000,  the  Marketing  Authorisation  Holder  applied  to  extend  the  shelf-life  of 
Viagra  from  3  to  4  years.  This  variation  falls  within  the  scope  of  item  No  20  of  Annex  I  of 
Commission Regulation (EC) No. 542/95 of 10 March 1995 as amended. The procedure started 
on  29  August  2000.  The  EMEA  considered  this  variation  to  be  acceptable  and  issued  on  
28 September 2000 a positive Notification. 
On 14 March 2001 the Marketing Authorisation Holder applied for the change of the name of a 
manufacturer  of the  active substance. This  variation  falls within the  scope of  item No.  11a  of 
Annex  I  of  Commission  Regulation  (EC)  No.  542/95  of  10  March  1995  as  amended.  
1/2 
EMEA 2005 
 
 
 
 
 
 
• 
• 
• 
The procedure started on 22 March 2001. The EMEA considered this variation to be acceptable 
and issued on 27 March 2001 a positive Notification. 
On 24 May 2001 the Marketing Authorisation Holder applied for changes to the SPC to include 
additional  information  available.  The  changes  concern  sections  4.8  (Undesirable  effects),  5.1 
(Pharmacodynamic  properties)  and  5.2  (Pharmacokinetic  properties).  The  CPMP  considered 
this Type II variation to be acceptable and adopted on 26 July 2001 an Opinion. The European 
Commission issued a favourable Decision on 27 November 2001. 
On 5th October 2001 the Marketing Authorisation Holder applied for an extension of shelf-life 
from  4  to  5  years.  The  procedure  started  on  12  October  2001.  The  EMEA  considered  this 
variation to be acceptable and issued on 9 November 2001 a positive Notification. 
On  14  November  2001  The  Marketing  Authorisation  Holder  applied  for  changes  to  the  SPC  
and  PL. This Type II variation relates to an update of section 5.1 of SPC to include additional 
information  available  on  severe  coronary  artery  disease  and  patients  with  erectile  dysfunction 
and stable angina. The CPMP considered this Type II variation to be acceptable and adopted on 
17  January  2002  an  Opinion.  The  European  Commission  issued  a  favourable  Decision  on  
18 April 2002.  
Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below: 
Scope 
Application 
number 
Type of 
modification1 
Change of Design of the Alum Foil 
Change following modification(s) to the manufacturing 
authorisation(s) – change in name of manufacturer. 
Minor change in package leaflet not connected with the SPC (Art. 
61.3 Notification) 
N/14 
I/15 
N/16 
N 
I 
N 
Notification/ 
Opinion 
issued on2 
15 March 
2002 
8 October 
2002 
15 November 
2002 
Commission 
Decision 
Issued/amended 
on 
- 
24 October 2002 
04 December 
2002 
1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers 
to a minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a 
minor variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an 
Annex II application. 
T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) 
No 2141/96 of 7 November 1996.  
N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 
March 1992. 
2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification 
date. The Commission Decision will be amended accordingly. 
2/2 
EMEA 2005 
 
 
 
 
 
 
 
 
 
                                                      
 
